Table 1: Definitions Used in the AJCC Lung Cancer Staging System
Table 2: AJCC Staging of NSCLC
Table 3: Symptoms of NSCLC
Table 4: Prognostic Factors for NSCLC
Table 5: Prognosis for NSCLC Based on Initial Staging
Table 6: Prevalence of Brain and Bone Metastases in NSCLC
Table 7: Biomarker Testing Rates in Nonsquamous NSCLC
Table 8: Biomarker Testing Rates in Squamous NSCLC
Table 9: Treatment Guidelines for NSCLC
Table 10: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015–2025
Table 11: Country Profile – France
Table 12: Country Profile – Germany
Table 13: Country Profile – Italy
Table 14: Country Profile – Spain
Table 15: Country Profile – UK
Table 16: Leading Treatments for NSCLC, 2016
Table 17: Marketed EGFR TKIs in NSCLC
Table 18: Product Profile – Tarceva
Table 19: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC
Table 20: Efficacy of Tarceva in Maintenance Therapy in NSCLC
Table 21: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC
Table 22: Safety of Tarceva
Table 23: Tarceva SWOT Analysis, 2016
Table 24: Product Profile – Iressa
Table 25: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1)
Table 26: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2)
Table 27: Safety of Iressa
Table 28: Iressa SWOT Analysis, 2016
Table 29: Product Profile – Gilotrif
Table 30: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 31: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 32: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Naïve, Squamous NSCLC
Table 33: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC
Table 34: Safety of Gilotrif
Table 35: Gilotrif SWOT Analysis, 2016
Table 36: Product Profile – Tagrisso
Table 37: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC
Table 38: Safety of Tagrisso
Table 39: Tagrisso SWOT Analysis, 2016
Table 40: Product Profile – Portrazza
Table 41: Efficacy of Portrazza in First-Line, Squamous NSCLC
Table 42: Safety of Portrazza
Table 43: Portrazza SWOT Analysis, 2016
Table 44: Efficacy of Conmana in 2L Advanced NSCLC
Table 45: Efficacy of Conmana in 1L EGFR-mutant NSCLC
Table 46: Safety of Conmana
Table 47: Conmana SWOT Analysis, 2016
Table 48: Marketed ALK TKIs in NSCLC
Table 49: Product Profile – Xalkori
Table 50: Efficacy of Xalkori in Treatment-Naïve ALK+ Metastatic NSCLC
Table 51: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC
Table 52: Safety of Xalkori in Treatment-Naïve, ALK+ Metastatic NSCLC
Table 53: Safety of Xalkori in Previously Treated, Metastatic NSCLC
Table 54: Xalkori SWOT Analysis, 2016
Table 55: Product Profile – Zykadia
Table 56: Efficacy of Zykadia
Table 57: Safety of Zykadia
Table 58: Zykadia SWOT Analysis, 2016
Table 59: Product Profile – Alecensa
Table 60: Efficacy of Alecensa
Table 61: Efficacy of Alecensa in NSCLC patients with CNS lesions
Table 62: Safety of Alecensa
Table 63: Alecensa SWOT Analysis, 2016
Table 64: Marketed PD-1/PD-L1 ICIs in NSCLC
Table 65: Product Profile – Opdivo
Table 66: Efficacy of Opdivo in Metastatic Squamous NSCLC
Table 67: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC
Table 68: Safety of Opdivo
Table 69: Opdivo SWOT Analysis, 2016
Table 70: Product Profile – Keytruda
Table 71: Efficacy of Keytruda
Table 72: Safety of Keytruda
Table 73: Keytruda SWOT Analysis, 2016
Table 74: Product Profile – Tecentriq (atezolizumab)
Table 75: Patient Demographics in the Phase II POPLAR Trial (NCT01903993)
Table 76: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 77: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227)
Table 78: Patient Demographics in the Phase II FIR Trial (NCT01846416)
Table 79: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 80: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458)
Table 81: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 82: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 83: Tecentriq SWOT Analysis, 2016
Table 84: Product Profile – Avastin
Table 85: Efficacy of Avastin in Nonsquamous NSCLC
Table 86: Safety of Avastin
Table 87: Avastin SWOT Analysis, 2016
Table 88: Product Profile – Cyramza
Table 89: Efficacy of Cyramza
Table 90: Safety of Cyramza
Table 91: Cyramza SWOT Analysis, 2016
Table 92: Product Profile – Vargatef
Table 93: Efficacy of Vargatef in ADC NSCLC
Table 94: Safety of Vargatef in ADC NSCLC
Table 95: Vargatef SWOT Analysis, 2016
Table 96: Summary of Chemotherapies, 2015
Table 97: Unmet Need and Opportunity in NSCLC
Table 98: Product Profile – Yervoy (ipilimumab)
Table 99: Demographics in the Phase II NCT00527735 Trial
Table 100: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 101: Demographics in the Phase I CheckMate 012 Trial (NCT01454102)
Table 102: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 103: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 104: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 105: Yervoy SWOT Analysis, 2016
Table 106: Product Profile – Avelumab (MSB-0010718C)
Table 107: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 108: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 109: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC
Table 110: Demographics in the Treatment-Naïve NSCLC Cohort in the Phase I Trial (NCT01772004)
Table 111: Efficacy of Avelumab in Treatment-Naïve NSCLC
Table 112: Unconfirmed ORR According to PD-L1 Expression in Treatment-Naïve NSCLC
Table 113: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 114: Safety of Avelumab in Treatment-Naïve NSCLC (NCT01772004)
Table 115: Avelumab SWOT Analysis, 2016
Table 116: Product Profile – Durvalumab (MEDI4736)
Table 117: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial
Table 118: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial
Table 119: Baseline Characteristics of Patients With Treatment-Naïve NSCLC in the Phase I/II
Table 120: Efficacy of Durvalumab in Treatment-Naïve NSCLC
Table 121: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial
Table 122: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 123: Safety of Durvalumab in the Phase I/II Trial (NCT01693562)
Table 124: Safety of Durvalumab in Treatment-Naïve NSCLC
Table 125: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 126: Durvalumab SWOT Analysis, 2016
Table 127: Product Profile – Naquotinib Mesylate (ASP8273)
Table 128: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials
Table 129: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 130: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 131: Naquotinib SWOT Analysis, 2016
Table 132: Product Profile – Olmutinib (BI 1482694; HM61713)
Table 133: Demographics in the Phase I/II NCT01588145 Trial
Table 134: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 135: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 136: Olmutinib SWOT Analysis, 2016
Table 137: Product Profile – Dacomitinib
Table 138: Demographics in the Phase II NCT00818441 Trial
Table 139: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial
Table 140: Safety of Dacomitinib in Phase II NCT00818441 Trial
Table 141: Dacomitinib SWOT Analysis, 2016
Table 142: Product Profile – Ensartinib
Table 143: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534)
Table 144: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 145: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial
Table 146: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534)
Table 147: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 148: Ensartinib SWOT Analysis, 2016
Table 149: Product Profile – Brigatinib
Table 150: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573)
Table 151: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 152: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases
Table 153: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 154: Brigatinib SWOT Analysis, 2016
Table 155: Product Profile – CimaVax-EGF
Table 156: Demographics in the Phase III trial of the CimaVax-EGF in Cuba
Table 157: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba
Table 158: Safety of the CimaVax-EGF in the Phase III Trial in Cuba
Table 159: CimaVax-EGF SWOT Analysis, 2016
Table 160: Product Profile – Tedopi
Table 161: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC
Table 162: Efficacy of Tedopi in Advanced NSCLC
Table 163: Tedopi SWOT Analysis, 2016
Table 164: Product Profile – Anlotinib
Table 165: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial
Table 166: Anlotinib SWOT Analysis, 2016
Table 167: Product Profile – Aitan
Table 168: Efficacy of Aitan in Pretreated Nonsquamous NSCLC
Table 169: Aitan SWOT Analysis, 2016
Table 170: Product Profile – Fruquintinib
Table 171: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib
Table 172: Efficacy of Fruquintinib in Advanced Solid Tumors
Table 173: Safety of Fruquintinib in Advanced Solid Tumors
Table 174: Fruquintinib SWOT Analysis, 2016
Table 175: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003)
Table 176: Product Profile – Abemaciclib
Table 177: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016)
Table 178: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636)
Table 179: Safety of Abemaciclib in Combination with Multiple Single Agents
Table 180: Abemaciclib SWOT Analysis, 2016
Table 181: Product Profile – Tafinlar + Mekinist
Table 182: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634)
Table 183: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 184: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 185: Tafinlar + Mekinist SWOT Analysis, 2016
Table 186: Product Profile – Veliparib
Table 187: Demographics in the Phase II NCT01560104 Trial
Table 188: Efficacy of VCP in Advanced NSCLC (NCT01560104)
Table 189: Efficacy of VCP by Smoking Status (NCT01560104)
Table 190: Safety of VCP in Advanced NSCLC (NCT01560104)
Table 191: Veliparib SWOT Analysis, 2016
Table 192: Product Profile – Seribantumab (MM-121)
Table 193: Demographics in Group A of the Phase I/II Trial (NCT00994123) of MM-121 + Tarceva in
Table 194: Efficacy of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 195: Safety of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 196: MM-121 SWOT Analysis, 2016
Table 197: Product Profile – Sacituzumab govitecan (IMMU-132)
Table 198: Demographics in the Phase II Portion of the Phase I/II Trial (NCT01631552)
Table 199: Efficacy of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 200: Efficacy of IMMU-132 in Patients Who Progressed on Prior Checkpoint Inhibitor
Table 201: Safety of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 202: IMMU-132 SWOT Analysis, 2016
Table 203: Product Profile – Plinabulin
Table 204: Efficacy of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 205: Safety of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 206: Plinabulin SWOT Analysis, 2016
Table 207: Early-Stage Clinical Development in NSCLC
Table 208: MET Status in the Phase II (NCT01610336) Trial
Table 209: Efficacy of Capmatinib + Iressa in MET+ NSCLC
Table 210: Demographics in the Phase II LURET Study
Table 211: Efficacy of Caprelsa in RET+ NSCLC
Table 212: Demographics in the Stage I of the Phase II NCT01639508 Trial
Table 213: Efficacy of Cometriq in RET+ NSCLC
Table 214: Key Events Impacting Sales for NSCLC in the 5EU, 2016
Table 215: NSCLC –Drivers and Barriers in the 5EU, 2015?2025
Table 216: Key Launch Dates – Part I
Table 217: Key Launch Dates – Part II
Table 218: Key Patent Expiries
Table 219 Average Body Weight and Surface Area Across the 8MM
Table 216: Average Cost of Therapy of Alimta in the 8MM
Table 217: Average Cost of Therapy of Alecensa in the 8MM
Table 218: Average Cost of Therapy of Avastin
Table 219: Average Cost of Therapy of Cyramza
Table 220: Average Cost of Therapy of Gilotrif
Table 221: Average Cost of Therapy of Iressa
Table 222: Average Cost of Therapy of Portrazza
Table 223: Average Cost of Therapy of Tagrisso
Table 224: Average Cost of Therapy of Tarceva
Table 225: Average Cost of Therapy of Vargatef
Table 226: Average Cost of Therapy of Xalkori
Table 227: Average Cost of Therapy of Zykadia
Table 228: Average Cost of Therapy of Keytruda
Table 229: Average Cost of Therapy of Opdivo
Table 230: Average Cost of Therapy of Tecentriq
Table 231: Average Cost of Therapy of Conmana
Table 232: High-Prescribing Physicians Surveyed by Country